Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists.
- Published In:
- Pharmaceuticals (Basel, Switzerland), 16(5) (2023)
- Authors:
- Nock, Berthold A, Kanellopoulos, Panagiotis, Joosten, Lieke, Mansi, Rosalba, Maina, Theodosia
- Database ID:
- RPEP-07227
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-07227APA
Nock, Berthold A; Kanellopoulos, Panagiotis; Joosten, Lieke; Mansi, Rosalba; Maina, Theodosia. (2023). Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists.. Pharmaceuticals (Basel, Switzerland), 16(5). https://doi.org/10.3390/ph16050674
MLA
Nock, Berthold A, et al. "Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists.." Pharmaceuticals (Basel, 2023. https://doi.org/10.3390/ph16050674
RethinkPeptides
RethinkPeptides Research Database. "Peptide Radioligands in Cancer Theranostics: Agonists and An..." RPEP-07227. Retrieved from https://rethinkpeptides.com/research/nock-2023-peptide-radioligands-in-cancer
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.